NEW YORK (GenomeWeb) – The New York State Department of Health has approved Response Genetics to market and report results from its ResponseDX tests to residents of the state, the company said today.
The New York approval follows a two-day inspection of Response Genetics' CLIA laboratory in September.
The company offers ResponseDX Biomarker tests for various cancer types, including lung, breast, and colon cancer. The tests use different technologies such as sequencing, PCR, and fluorescence in situ hybridization. Response Genetics also offers the microarray-based ResponseDX: Tissue of Origin Test for identifying challenging tumors, such as metastatic, poorly differentiated, and undifferentiated cancer.
Response Genetics acquired the test when it bought the assets of Pathwork Diagnostics in 2013.